10-K: Century Therapeutics Narrows Losses, Secures Funding into 2029

Century Therapeutics reported a significant reduction in net loss for 2025, driven by collaboration revenue, and extended its cash runway into Q1 2029 with a recent private placement, while reprioritizing its cell therapy pipeline.

Summary

• Net loss significantly decreased to $9.6 million for the year ended December 31, 2025, compared to $126.6 million in 2024.
• Collaboration revenue surged to $109.2 million in 2025 from $6.6 million in 2024, primarily due to the recognition of deferred revenue from the terminated Bristol-Myers Squibb agreement.
• Research and development expenses decreased by $11.6 million to $95.7 million in 2025, mainly due to a reduction in R&D staff and completion of a manufacturing campaign under the FCDI collaboration.
• General and administrative expenses decreased by $9.2 million to $24.0 million in 2025, attributed to lower legal fees, a gain on lease modification, a gain on reduction of contingent consideration liability, and decreased stock-based compensation.
• The company recorded a $6.8 million impairment charge on long-lived assets in 2025 related to a portion of its Philadelphia headquarters lease asset.
• Goodwill impairment of $4.3 million was recorded in 2024, with no similar expense in 2025.
• Cash, cash equivalents, and investments totaled $117.1 million as of December 31, 2025.
• An additional $126.7 million in net proceeds was received from a private placement in January 2026, extending the cash runway into the first quarter of 2029.
• The pipeline was reprioritized in November 2025, focusing on CNTY-813 (beta islet program for T1D) and CNTY-308 (CD19-targeted CAR-iT for B-cell mediated diseases), both in IND-enabling studies.
• Clinical development activities for CNTY-101 (CAR-iNK cell therapy) are prioritized in the CARAMEL Phase 1/2 investigator-sponsored trial for B-cell-mediated autoimmune diseases, with initial data presented in December 2025.
• The company operates a 53,000 square foot cell therapy manufacturing facility in Branchburg, New Jersey, operational since 2022, and received EU GMP compliance declaration in February 2025.
• The Bristol-Myers Squibb Collaboration Agreement was terminated effective March 12, 2025, resulting in no future collaboration revenues from this agreement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing. The substantial reduction in net loss and the significant capital raise extending the cash runway into 2029 provide a strong financial foundation. The strategic pipeline reprioritization, while pushing commercialization timelines further out, focuses on potentially transformative iPSC-derived therapies, indicating a clear path forward despite the inherent early-stage risks of biotech development.

Positives

• Net loss significantly reduced to $9.6 million in 2025 from $126.6 million in 2024, indicating improved financial performance.
• Collaboration revenue increased substantially to $109.2 million in 2025, providing a significant cash inflow.
• Successful private placement in January 2026 raised $126.7 million in net proceeds, extending the company's cash runway into Q1 2029.
• Strategic reprioritization of the pipeline focuses resources on high-potential, earlier-stage programs (CNTY-813 and CNTY-308) with anticipated IND submissions in 2026.
• CNTY-813 demonstrated functional glucose control and immune protection in pre-clinical models, with a scalable manufacturing process.
• CNTY-308 showed potent anti-tumor cytotoxicity, cytokine production, and proliferation comparable to primary CAR-T cells in preclinical studies.
• CNTY-101 is advancing in a Phase 1/2 investigator-sponsored trial (CARAMEL) for B-cell-mediated autoimmune diseases, with initial data presented in December 2025.
• In-house GMP manufacturing facility in Branchburg, New Jersey, is operational and received EU compliance, enhancing control over manufacturing and reducing supply risk.
• The company holds a strong intellectual property portfolio, including issued US patents for its safety switch construct and universal CAR cell platform, with applications for Allo-Evasion technology and product candidates.

Negatives

• The significant increase in collaboration revenue in 2025 was primarily due to the recognition of deferred revenue from the termination of the Bristol-Myers Squibb Collaboration Agreement, not new product sales.
• The company has incurred significant operating losses since inception, with an accumulated deficit of $791.9 million as of December 31, 2025.
• No product candidates are currently approved for commercial sale, and the company does not expect to generate revenue from product sales for many years.
• The strategic reprioritization towards earlier-stage programs may extend development timelines and increase capital requirements before product revenue can be generated.
• An impairment charge of $6.8 million was recorded on long-lived assets in 2025, related to a portion of the Philadelphia headquarters lease.
• The company implemented a reduction in force in July 2025, which may affect employee morale and retention.
• Reliance on third-party suppliers for critical reagents and materials poses supply chain risks and potential for inconsistent product attributes.
• The company has limited experience designing and implementing late-stage clinical trials, increasing the risk of delays or failures.
• The intellectual property landscape for gene-editing technology is highly dynamic and uncertain, with potential for litigation and challenges to patent rights.

Risks

• Incurring significant losses for the foreseeable future and requiring additional funding to finance operations.
• Inability to generate revenue from product sales or achieve and maintain profitability.
• Dependence on the successful advancement of early-stage product candidates (CNTY-813, CNTY-308) through preclinical and clinical trials, and obtaining marketing approval.
• Challenges associated with the novel approach of genetically engineered iPSC-derived immune cells and beta islet cells for cancer and autoimmune diseases.
• Risks related to gene-editing technology, including unintended DNA changes and competitive pressures from new technologies.
• Lengthy and expensive preclinical and clinical development processes with uncertain outcomes, potentially leading to additional costs or delays.
• Limited organizational experience in designing or implementing clinical trials, which could affect trial initiation, patient enrollment, completion, or regulatory approval.
• Complexities and risks in manufacturing and distributing iPSC-derived cell product candidates, potentially increasing costs and limiting supply.
• Dependence on the availability of FDA-acceptable reagents, specialized materials, and equipment, with potential supply chain disruptions.
• Operational issues in manufacturing facilities (internal or third-party) could delay development plans and revenue generation.
• Strategic collaborations may not materialize, or the company may be required to relinquish important rights to product candidates.
• Changes in regulatory requirements, guidance, or unanticipated events during studies and trials could lead to increased costs and delays.
• Termination of license agreements with FUJIFILM Cellular Dynamics, Inc. (FCDI) could result in the loss of rights to key iPSC-derived cell therapy platform components.
• Inability to obtain, protect, maintain, and enforce intellectual property rights, including for product candidates without issued patents.
• Claims by third parties of intellectual property infringement, misappropriation, or violation, leading to damages or delays.
• Volatility of capital markets and macroeconomic factors (inflation, banking instability, geopolitical tensions) impacting funding access and stock price.
• Adverse developments in the financial services industry affecting liquidity and access to cash.
• Potential for adverse events or undesirable side effects from product candidates, delaying approval or limiting commercialization.
• Negative public opinion and scrutiny of cell-based and genetically engineered therapies impacting public perception and business operations.
• Restrictions on animal testing affecting research and development activities.
• Failure to meet projected development goals and milestones, delaying product commercialization.
• Difficulties in identifying and enrolling patients in future clinical trials.
• FDA not accepting data from trials conducted outside the United States.
• Risk of expending limited resources on less profitable or successful product candidates.
• Uncertainty regarding the pricing of product candidates and potential pricing pressures from healthcare reform.
• Uncertainty of insurance coverage and reimbursement for newly approved products.
• Ongoing regulatory oversight and potential for significant restrictions or post-approval studies even after marketing approval.
• Failure to achieve broad market acceptance for approved product candidates.
• Inability to establish effective marketing, sales, and distribution capabilities.
• Market opportunities for product candidates being smaller than anticipated.
• Fluctuations in operating results due to various factors, making future results difficult to predict.
• Dependence on key management and scientific personnel, with risks of retention issues and impact from workforce reductions.
• Difficulties in managing organizational growth and expanding capabilities.
• Noncompliance with foreign, federal, and state healthcare and privacy laws and regulations, leading to penalties or reputational harm.
• Risks and challenges posed by artificial intelligence, including security risks and an uncertain regulatory environment.
• Risks associated with the increasing use of social media platforms, including adverse event reporting and reputational harm.
• Claims challenging the inventorship or ownership of patents and other intellectual property.
• Inadequate patent terms to protect competitive position for an adequate amount of time.
• Inability to protect intellectual property rights throughout the world, especially in countries with less extensive protection.

Future Outlook

The company anticipates submitting an Investigational New Drug (IND) application for CNTY-813 (beta islet program for T1D) as early as 2026 and expects to initiate clinical studies for CNTY-308 (CD19-targeted CAR-iT cell therapy) in 2026, following successful completion of IND-enabling studies and regulatory authorization. Preliminary data from the CARAMEL IST for CNTY-101 is expected to be shared in 2026. The company expects expenses and operating losses to increase substantially in the foreseeable future as it expands R&D, progresses preclinical and clinical development, seeks regulatory approvals, and builds manufacturing capabilities. Additional financing will be required in the future beyond the current cash runway into Q1 2029.

Management Comments

• Our vision is to become a premier, fully integrated biotechnology company by developing and ultimately commercializing off-the-shelf allogeneic cell therapies that dramatically and positively transform the lives of patients suffering from T1D, autoimmune diseases and cancers.
• We believe our iPSC-derived platform affords us a significant opportunity to advance multiplex gene-edited cell therapies that can be produced at a substantially lower cost and accessible by a much larger patient population as compared to other donor-derived and autologous cell therapy approaches.
• We believe our investment in in-house manufacturing will enable us to analyze, learn and adapt more rapidly, and increase control of development and manufacturing timelines for efficient clinical development of our product candidates.
• We believe our existing facilities are adequate to support our ongoing business needs.

Industry Context

StockSavvy.ai notes that Century Therapeutics is positioning itself in the highly competitive and rapidly evolving field of allogeneic cell therapies, specifically leveraging iPSC technology for immuno-oncology and autoimmune diseases, including Type 1 Diabetes. The focus on 'off-the-shelf' therapies addresses key limitations of autologous treatments (scalability, availability, cost). The company's proprietary Allo-Evasion technology aims to differentiate its products by preventing immune rejection and enabling repeat dosing, a critical advantage in cell therapy. While the pipeline is still early-stage, the strategic reprioritization towards beta islet and CAR-iT programs, alongside the ongoing CAR-iNK trial, indicates a diversified approach within the iPSC space. The termination of the Bristol-Myers Squibb collaboration, while impacting future revenue streams, allowed for a significant one-time revenue recognition in 2025, providing a temporary boost to the financial statements. The industry continues to see substantial investment and competition from both large pharmaceutical companies (e.g., AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, Roche) and emerging biopharmaceutical firms (e.g., Adicet Bio, Allogene Therapeutics, Vertex Pharmaceuticals, CRISPR Therapeutics), highlighting the need for Century to rapidly advance its novel platforms to maintain a competitive edge.

Comparison to Industry Standards

• Century's iPSC-derived beta islets demonstrate equivalent function in vitro and in vivo to human cadaveric islets, which are currently limited by supply and quality, and require lifelong immunosuppression.
• CNTY-308's ab iT cells display potent cytotoxicity, cytokine secretion, target-driven proliferation, and cell persistence comparable to primary CAR-T cells, which are the basis for successful autologous CAR T cell therapies in oncology and autoimmune diseases.
• The company's Allo-Evasion technology aims to overcome immune rejection, potentially reducing or eliminating the need for lymphodepleting chemotherapy (LDC) or ongoing immune suppression, a significant challenge for existing autologous CAR-T therapies (e.g., those from Gilead Sciences, Novartis, Bristol-Myers Squibb) that require LDC and carry risks like prolonged cytopenias and neurotoxicities.
• CNTY-101, as an allogeneic iNK product, is expected to offer a favorable clinical tolerability profile and precise control of drug exposure through repeat dosing, potentially avoiding extended B-cell aplasia seen with T cell treatments in autoimmune diseases like SLE, LN, IIM, and DcSSc, where current therapies (e.g., anifrolumab) show suboptimal responses in many patients.
• The company's manufacturing approach aims for substantially lower cost and higher batch-to-batch consistency compared to other donor-derived and autologous cell therapy approaches, which are often challenged by high COGs and scalability issues.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• May become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business from time to time.

Related Party Transactions

• Exclusive and non-exclusive license agreements with FUJIFILM Cellular Dynamics, Inc. (FCDI), a shareholder, for iPSC differentiation and reprogramming technology.
• Master Collaboration Agreement with FCDI for research and development services.
• Manufacturing Agreement with FCDI for technology transfer, process development, analytical testing, and cGMP manufacturing services.
• Letter Agreement with FCDI amending existing FCDI agreements, including an upfront payment of $10.0 million and percentages of future milestone/royalty payments related to Japan.
• Autoimmune License with FCDI for non-exclusive licenses related to iPSC-derived therapies for inflammatory and autoimmune diseases, involving development/regulatory milestone payments and low single-digit royalties, with an upfront payment of $4.0 million and a $1.0 million milestone fee paid in 2023.
• Option agreement with Bayer HealthCare LLC, a shareholder, granting Bayer certain bidding rights for potential transfer of rights to Research Products (allogeneic iNK cells, macrophages, or dendritic cells), excluding T cell programs and CNTY-101.
• Sublicense agreement with iCELL Inc. for patents related to immune function reconstruction and antigen-specific T-cells, involving low single-digit royalties on net sales and up to $70.0 million in sales milestones, plus $4.25 million in development and regulatory milestone payments.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future equity financings, but also potential for long-term value creation if pipeline candidates achieve commercial success. Recent private placement provides near-term stability.
• **Employees:** Reduction in force in July 2025 may impact morale and retention, but strategic reprioritization aims to align workforce with core objectives. Continued investment in R&D and manufacturing indicates future growth opportunities.
• **Patients:** Development of off-the-shelf allogeneic cell therapies (CNTY-813 for T1D, CNTY-308 for B-cell mediated diseases, CNTY-101 for autoimmune diseases) aims to provide more accessible, reliable, and potentially curative treatments for serious unmet medical needs.
• **Regulatory Bodies:** Ongoing engagement with FDA and foreign regulatory authorities for IND submissions and clinical trial approvals, with a focus on novel iPSC-derived therapies, requiring adherence to evolving guidelines.
• **Partners/Licensors (FCDI, Bayer, iCELL, Catalent):** Continued collaboration and licensing agreements are crucial for technology access and development. Termination of the Bristol-Myers Squibb agreement highlights the dynamic nature of partnerships.

Next Steps

• Advance CNTY-813 (beta islet program for T1D) through IND-enabling studies.
• Submit an IND application for CNTY-813 as early as 2026.
• Complete IND-enabling studies for CNTY-308 (CD19-targeted CAR-iT cell therapy).
• Initiate clinical studies for CNTY-308 in 2026, following regulatory authorization.
• Continue supporting the CARAMEL Phase 1/2 investigator-sponsored trial for CNTY-101 in B-cell-mediated autoimmune diseases.
• Share preliminary data from the CARAMEL IST in 2026.
• Seek to discover and develop additional product candidates.
• Expand and validate internal clinical-scale cGMP facilities.
• Seek regulatory approvals for product candidates that successfully complete clinical trials.
• Maintain, expand, protect, and enforce the intellectual property portfolio.
• Acquire or in-license other product candidates and technologies.
• Selectively evaluate strategic partnerships to enable greater patient access and accelerate development/delivery of therapies.

Key Dates

Recommendation

The company's financial position has significantly improved in 2025, largely due to the recognition of deferred revenue from a terminated collaboration, and a substantial capital raise in early 2026 provides a solid cash runway into 2029. This reduces immediate liquidity concerns. However, the pipeline is still in early-stage development, with lead candidates (CNTY-813, CNTY-308) in IND-enabling studies and CNTY-101 in a Phase 1/2 IST. Commercialization is several years away, and significant future funding will be required. The strategic reprioritization, while potentially beneficial long-term, introduces uncertainty regarding development timelines and market acceptance of novel iPSC-derived therapies. Given the early stage of the assets, the inherent risks of biotech development, and the need for further clinical validation, a 'hold' recommendation is appropriate for a seasoned investor, acknowledging the improved financial stability but emphasizing the long-term, high-risk nature of the investment.

Keywords

Cell Therapy, iPSC, Induced Pluripotent Stem Cells, Gene Editing, CRISPR, Allogeneic, Autoimmune Diseases, Type 1 Diabetes, T1D, Oncology, CAR-T Cell Therapy, CAR-NK Cell Therapy, Beta Islet Cells, Allo-Evasion Technology, Biotechnology, Pharmaceutical, Clinical Trials, Preclinical Development, Regulatory Approval, Manufacturing, Intellectual Property, Financial Performance, Capital Raise